Latest Conference Articles

According to findings from the phase III CELESTIAL trial released ahead of the 2018 Gastrointestinal Cancers Symposium, cabozantinib (Cabometyx) improved median overall survival by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma.

Patients with heavily pretreated gastrointestinal stromal tumors responded to treatment with nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy), according to findings of a randomized phase II study presented at the 2018 Gastrointestinal Cancers Symposium.

According to data from a randomized phase III trial presented at the 2017 San Antonio Breast Cancer Symposium, a mix of traditional and customized acupuncture techniques were effective in reducing pain and stiffness associated with aromatase inhibitor therapy in women with early-stage breast cancer.

Christian Jackisch, MD, PhD, Professor of Obstetrics and Gynecology and Head of the Department of Obsterics and Gynaecology, Sana Klinikum Offenbach in Germany, discusses results of the GeparSepto study, as well as how a higher pathologic complete response (pCR) rate is achieved with nab-paclitaxel (Abraxane) in breast cancer.

According to findings presented at the 2017 San Antonio Breast Cancer Symposium, no significant efficacy was seen in a trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein.

Ivosidenib (AG-120), an IDH1 inhibitor, demonstrated an objective response rate (ORR) of 41.6% in patients&nbsp;with relapsed/refractory&nbsp;<em>IDH1</em>-mutant acute myeloid leukemia (AML), according to findings from a single-arm phase I study.&nbsp;

Treatment with pegylated interferon alfa-2a led to objective responses in about two-thirds of patients with hydroxyurea (Hydrea)-resistant/intolerant polycythemia vera or high-risk essential thrombocytopenia, a phase II study of salvage therapy showed.

Srdan Verstovsek, MD, of MD Anderson Cancer Center, discusses a study of sotatercept (ACE-011) alone and in combination with ruxolitinib in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.

A novel pegylated formulation of interferon alfa-2b achieved a significantly higher rate of complete hematologic response compared with hydroxyurea (Hydrea) in patients with polycythemia vera, according to 2-year findings from the follow-up phase III CONTI-PV randomized trial.

The investigational activin receptor IIA ligand trap sotatercept safely increases hemoglobin levels in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis, both when used alone and in combination with ruxolitinib (Jakafi).

Joshua Richter, MD, Hackensack University Medical Center, discusses a tool which explored the incidence and survival impact of self-reported symptoms and psychologic distress among patients with multiple myeloma during the 2017 ASH Annual Meeting.

The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera.<br /> &nbsp;

Daratumumab (Darzalex) in combination with VMP (bortezomib [Velcade], melphalan, and prednisone) could become a new standard of care for patients with newly diagnosed multiple myeloma who are unable to undergo transplant following findings from the phase III ALCYONE study.

Following autologous stem cell transplant (ASCT) for patients with multiple myeloma, maintenance therapy of elotuzumab (Empliciti) in combination with lenalidomide (Revlimid) led to an increased rate of response conversions from prior induction therapy, according to the results of a phase II study.&nbsp;

In the final analysis of the phase III ASPIRE trial, an improvement in survival was confirmed with the combination of&nbsp;carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone for patients with&nbsp;relapsed/refractory multiple myeloma, according to findings presented at the 2017 ASH Annual Meeting.

Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting.

In findings from the phase II CENTAURUS clinical trial, treatment with&nbsp;daratumumab&nbsp;(Darzalex) monotherapy produced lasting responses in patients with&nbsp;intermediate- and high-risk smoldering multiple myeloma (SMM).&nbsp;

A novel approach to treatment for patients with smoldering multiple myeloma demonstrated a high rate of complete responses, according to a study presented at the 2017 ASH Annual Meeting.&nbsp;The single-arm, phase II trial evaluated a strategy using induction therapy with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone followed by high-dose therapy and autologous stem cell transplantation, consolidation therapy and then maintenance therapy with lenalidomide and dexamethasone.

Chimeric antigen receptor T-cell therapy with bb2121 demonstrated an objective response rate of 94% in patients with&nbsp;relapsed/refractory multiple myeloma, according to findings from a dose-escalation study. The senior study author, James N. Kochenderfer, MD, presented updated findings from the study during the 2017 ASH Annual Meeting, and commented that 89% of patients had a very good partial response or better, and 56% of patients had a complete remission.&nbsp;<br /> &nbsp;

Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.<br /> &nbsp;

The combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) demonstrated promising clinical activity in patients with&nbsp;relapsed/refractory Hodgkin lymphoma,&nbsp;according to results from a phase I/II trial presented at the 2017 ASH Annual Meeting.

Treatment with the novel PD-1 inhibitor cemiplimab induced responses in half of the patients with&nbsp;Hodgkin lymphoma in a phase I study of patients with B-lymphoid malignancies; among patients with&nbsp;B-cell non-Hodgkin lymphoma treated with the monotherapy, the overall response rate was 11.1%, according to a poster presentation at the 2017 ASH Annual Meeting.&nbsp;

Treatment with&nbsp;tisagenlecleucel (Kymriah) continues to excite the possibilities seen with chimeric antigen receptor T-cell therapy with impressive responses seen with the therapy in patients with&nbsp;relapsed/refractory diffuse large B-cell lymphoma. In the phase II JULIET trial, an overall response rate of 53.1%&nbsp;was observed, according to findings presented at the ASH Annual Meeting.&nbsp;

Treatment with&nbsp;ladiratuzumab vedotin demonstrated an estimated median progression-free survival (PFS) of 11.6 weeks for patients with heavily pretreated metastatic triple-negative breast cancer (TNBC) treated&nbsp; with the recommended phase II dose of the antibody&ndash;drug conjugate, according to results of a phase I study presented during the 2017 San Antonio Breast Cancer Symposium.&nbsp;

Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the 5-year follow-up of the CALGB 40502 study for patients with triple-negative breast cancer (TNBC).

Treatment discontinuation due to toxicity was less frequent with olaparib (Lynparza) monotherapy compared with chemotherapy in patients with HER2-negative metastatic breast cancer and a germline <em>BRCA</em> mutation in the phase III OlympiAD study.

Ruben A. Mesa, MD, Director of the UT Health San Antonio Cancer Center, discusses &nbsp;4-year follow-up results from the phase III RESPONSE trial, which investigated ruxolitinib (Jafaki) with best available therapy for the treatment of polycythemia vera (PV) during the 2017 ASH Annual Meeting.

Adding rituximab (Rituxan) to ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) did not improve progression-free survival (PFS) or overall survival (OS) versus ibrutinib alone, despite there being a faster time to complete remission.

According to results of a phase Ib/II trial presented at the 2017 ASH Annual Meeting, the frontline triplet regimen of atezolizumab (Tecentriq), obinutuzumab (Gazyva), and bendamustine was associated with an overall response rate (ORR) of 85% (Modified Lugano criteria; independent review) in patients with follicular lymphoma.

Jesus Berdeja, MD, Director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses results of a study that explored bb2121, an anti-BCMA CAR T cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma during the 2017 ASH Annual Meeting.